22:21 , Oct 12, 2017 |  BC Innovations  |  Targets & Mechanisms

Mining the negatives

By investigating why its discontinued siRNA candidate against hepatitis B caused only weak responses in certain patients, Arrowhead Pharmaceuticals Inc. has upended a dogma about the virus’ genetics that has been clouding drug design and...
16:30 , Aug 18, 2017 |  BC Week In Review  |  Company News

GSK declines option to Ionis' inotersen

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) said GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) declined its exclusive option to license inotersen ahead of regulatory submissions, which would have triggered a $45 million milestone payment to Ionis. The pharma also declined...
22:53 , Aug 11, 2017 |  BC Extra  |  Company News

GSK declines option to Ionis' inotersen

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) said GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) declined its exclusive option to license inotersen ahead of regulatory submissions, which would have triggered a $45 million milestone payment to Ionis. The pharma also declined...
07:00 , Mar 24, 2016 |  BC Innovations  |  Product R&D

Liver-bound

Ionis Pharmaceuticals Inc. is retooling its antisense technology with a sugar-based conjugate that boosts uptake into liver cells. By tapping the power of GalNAc sugars to latch onto hepatocyte receptors, the company believes it can...